SEC Form 4 · accession 0001817199-26-000024
Nurix Therapeutics, Inc. · NRIX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christine Ring
Officer — Chief Legal Officer
Period of report
Jul 2, 2026
Accepted (ET)
Jul 2, 2026 · 6:02 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001549595
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 2, 2026 | M | 5,221 | $1.86 | A | 18,800 | D | |
| Common Stock | Jul 2, 2026 | M | 5,787 | $8.72 | A | 24,587 | D | |
| Common StockF2 | Jul 2, 2026 | S | 11,008 | $23.5616 | D | 13,579 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $1.86 | Jul 2, 2026 | M | 5,221 | D | — | Sep 30, 2029 | Common Stock | 5,221 | 0 | D |
| Employee Stock Option (right to buy)F4 | $8.72 | Jul 2, 2026 | M | 5,787 | D | — | Feb 12, 2034 | Common Stock | 5,787 | 128,611 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
- F2Represents the weighted average sale price. The lowest price at which shares were sold was $23.23 and the highest price at which shares were sold was $24.16. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.
- F4The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.